Atrion (NASDAQ:ATRI) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI) in a report issued on Sunday. The brokerage set a “sell” rating on the medical instruments supplier’s stock.

Atrion Price Performance

ATRI stock opened at $459.66 on Friday. Atrion has a 1 year low of $274.98 and a 1 year high of $503.24. The company has a 50 day simple moving average of $455.77 and a 200 day simple moving average of $428.16. The stock has a market cap of $809.00 million, a price-to-earnings ratio of 43.20 and a beta of 0.69.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The firm had revenue of $48.77 million during the quarter.

Institutional Investors Weigh In On Atrion

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its stake in shares of Atrion by 3.6% in the first quarter. BNP Paribas Financial Markets now owns 723 shares of the medical instruments supplier’s stock valued at $335,000 after buying an additional 25 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Atrion by 5.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 552 shares of the medical instruments supplier’s stock worth $250,000 after purchasing an additional 29 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Atrion by 12.7% during the 2nd quarter. Principal Financial Group Inc. now owns 681 shares of the medical instruments supplier’s stock valued at $308,000 after acquiring an additional 77 shares during the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Atrion during the 4th quarter valued at about $36,000. Finally, Oppenheimer Asset Management Inc. lifted its position in Atrion by 12.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 1,105 shares of the medical instruments supplier’s stock worth $512,000 after buying an additional 118 shares during the last quarter. 66.19% of the stock is owned by institutional investors.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.